Efficacy and Safety of GTR in Comparison to Copaxone®
Public ClinicalTrials.gov record NCT01489254. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, 9 Month, Equivalence Trial Comparing the Efficacy and Safety and Tolerability of GTR (Synthon BV) to Copaxone® (Teva) in Subjects With Relapsing Remitting Multiple Sclerosis Followed by an Open-label 15 Month GTR Treatment Part Evaluating the Long-term GTR Treatment Effects
Study identification
- NCT ID
- NCT01489254
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Synthon BV
- Industry
- Enrollment
- 794 participants
Conditions and interventions
Conditions
Interventions
- Glatiramer Acetate (GTR) Drug
- Glatiramer Acetate (Copaxone®) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2011
- Primary completion
- Dec 31, 2014
- Completion
- Dec 31, 2014
- Last update posted
- Dec 28, 2016
2011 – 2015
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Synthon investigational site 112 | Irvine | California | — | — |
| Synthon investigational site 120 | Port Charlotte | Florida | — | — |
| Synthon investigational site 130 | Sunrise | Florida | — | — |
| Synthon investigational site 107 | Elk Grove Village | Illinois | — | — |
| Synthon investigational site 141 | Raleigh | North Carolina | — | — |
| Synthon investigational site 106 | Cleveland | Ohio | — | — |
| Synthon investigational site 135 | Dayton | Ohio | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 126 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01489254, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 28, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01489254 live on ClinicalTrials.gov.